Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience

ObjectivesImmune checkpoint inhibitors (ICIs) stimulate antitumor immune responses and, in parallel, they might trigger autoimmune and other immunopathological mechanisms eventually leading to immune-related adverse events (irAE). In our study, we assessed patients with malignancies who underwent an...

Full description

Bibliographic Details
Main Authors: Enikő Sebestyén, Nóra Major, Levente Bodoki, Attila Makai, Ingrid Balogh, Gábor Tóth, Zsuzsanna Orosz, Péter Árkosy, Attila Vaskó, Katalin Hodosi, Zoltán Szekanecz, Éva Szekanecz
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
immune-checkpoint inhibitors
immune-related adverse events
anti-PD-1
nivolumab
pembrolizumab
Central-Eastern Europe
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1252215/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1252215/full

Similar Items